- Home
- NRXS vs HYFT Comparison
NRXS vs HYFT Comparison
Compare NRXS & HYFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NRXS | HYFT |
|---|---|---|
| Founded | 2011 | 1983 |
| Country | United States | United States |
| Employees | N/A | 102 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.9M | 71.9M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | NRXS | HYFT |
|---|---|---|
| Price | $7.43 | $1.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $13.00 | $5.00 |
| AVG Volume (30 Days) | 177.3K | ★ 282.7K |
| Earning Date | 05-12-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.13 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,569,282.00 | N/A |
| Revenue This Year | $172.91 | N/A |
| Revenue Next Year | $115.71 | $29.18 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 32.89 | N/A |
| 52 Week Low | $2.20 | $0.99 |
| 52 Week High | $9.33 | $3.00 |
Technical Indicators
Market Signals| Indicator | NRXS | HYFT |
|---|---|---|
| Relative Strength Index (RSI) | 44.43 | 71.03 |
| Support Level | $6.80 | $1.56 |
| Resistance Level | $8.03 | $2.17 |
| Average True Range (ATR) | 0.63 | 0.14 |
| MACD | -0.16 | 0.04 |
| Stochastic Oscillator | 8.97 | 63.24 |
Price Performance
Historical ComparisonAbout NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
About HYFT MindWalk Holdings Corp.
MindWalk Holdings Corp is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT technology and the LensAI platform, MindWalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.